Connect with us

Life Sciences

Vial Partners with Egnyte to Integrate Life Sciences’ eTMF Solution into Their Clinical Trial Platform

Vial, a technology-first CRO, has announced a partnership with Egnyte, a leader in cloud content security and governance, to integrate its Life Sciences…

Published

on

This article was originally published by AITHORITY
Vial Partners with Egnyte to Integrate Life Sciences' eTMF Solution into Their Clinical Trial Platform

Vial, a technology-first CRO, has announced a partnership with Egnyte, a leader in cloud content security and governance, to integrate its Life Sciences eTMF (electronic trial master file) solution into Vial’s platform. Egnyte eTMF is a 21 CFR Part 11 compliant platform that reduces document processing time, maintains compliance, and increases audit readiness for life sciences companies.

Vial is a global, technology-driven CRO delivering faster, more efficient trials at dramatically lower costs for biotech sponsors. Vial’s next-generation technology integrates trial onboarding, patient enrollment, site communication, and data collection processes into one connected system. By deploying technology in every step of a trial, we are driving efficiencies in speed and cost that we pass on to innovative biotech startups.

Recommended AI: QuickLogic Drives eFPGA Innovation with New Aurora Development Tool Suite

“By integrating Egnyte’s eTMF, Vial will be able to offer our clients the gold standard in eTMF management, compliance, and audit readiness. We’re thrilled to be able to constantly increase the bar in clinical trial technology,” said Joshua Ondatje, Vice President of Clinical Operations at Vial.

With Egnyte for Life Sciences’ eTMF, clinical development professionals can easily create an eTMF to manage the thousands of documents collected through a trial and ensure those documents are properly stored and managed. Vial will be deeply integrating Egnyte’s eTMF automation features into its end-to-end clinical trial technology stack. Vial will be able to offer automated document upload, review, approval, and storage—saving time and money while maximizing compliance.

Recommended AI: Philips Speech and Sembly AI Launch SmartMeeting As Answer To New Meeting Culture

Egnyte for Life Sciences’ eTMF solution enables clinical development professionals to:

  • Simply manage, review, and stay on track with milestones: built on Egnyte’s leading secure collaboration platform, clinical professionals have full visibility into study milestones, allowing their teams to communicate with sites and stick to timelines.
  • Be audit-ready and compliant: the solution meets GxP and FDA 21 CFR Part 11 requirements so teams can stay audit-ready and maintain compliance in a cloud-based solution.
  • Accelerate TMF creation: reduce the administrative burden for clinical teams to stay organized with predefined reference models and standard artifacts.

“Egnyte’s eTMF solution is designed to meet the needs of the growing class of emerging and midsize biosciences companies,” said Ronen Vengosh, Vice President of Life Sciences at Egnyte. “By capitalizing on the simplicity and ease of the Egnyte for Life Sciences platform, Vial will be able to alleviate the data management burdens associated with trial studies, so clinical teams can focus on their core mission – getting safe and effective treatments to market quickly.”

Recommended AI: UTB Bot Unveils a New Way to Leverage Automation and Cryptocurrencies

[To share your insights with us, please write to sghosh@martechseries.com]

The post Vial Partners with Egnyte to Integrate Life Sciences’ eTMF Solution into Their Clinical Trial Platform appeared first on AiThority.



life sciences

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending